Status:
COMPLETED
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary...
Eligibility Criteria
Inclusion
- female patients, \>/=18 years of age
- epithelial ovarian, fallopian tube or primary peritoneal cancer
- platinum-resistant disease (disease progression within \<6 months of platinum therapy)
- EOCG performance status of 0-2
Exclusion
- non-epithelial tumours
- ovarian tumours with low malignant potential
- previous treatment with \>2 chemotherapy regimens
- prior radiotherapy to the pelvis or abdomen
Key Trial Info
Start Date :
October 29 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 9 2014
Estimated Enrollment :
361 Patients enrolled
Trial Details
Trial ID
NCT00976911
Start Date
October 29 2009
End Date
July 9 2014
Last Update
June 21 2022
Active Locations (117)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Jules Bordet
Brussels, Belgium, 1000
2
UZ Antwerpen
Edegem, Belgium, 2650
3
UZ Leuven Gasthuisberg
Leuven, Belgium, 3000
4
Clinique Ste-Elisabeth
Namur, Belgium, 5000